- Home
- DTSS vs LPCN Comparison
DTSS vs LPCN Comparison
Compare DTSS & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTSS
- LPCN
- Stock Information
- Founded
- DTSS 2014
- LPCN 1997
- Country
- DTSS China
- LPCN United States
- Employees
- DTSS N/A
- LPCN N/A
- Industry
- DTSS Computer Software: Prepackaged Software
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- DTSS Technology
- LPCN Health Care
- Exchange
- DTSS Nasdaq
- LPCN Nasdaq
- Market Cap
- DTSS 16.5M
- LPCN 16.1M
- IPO Year
- DTSS N/A
- LPCN N/A
- Fundamental
- Price
- DTSS $2.00
- LPCN $3.29
- Analyst Decision
- DTSS
- LPCN Strong Buy
- Analyst Count
- DTSS 0
- LPCN 2
- Target Price
- DTSS N/A
- LPCN $9.00
- AVG Volume (30 Days)
- DTSS 82.5K
- LPCN 59.4K
- Earning Date
- DTSS 05-14-2025
- LPCN 08-07-2025
- Dividend Yield
- DTSS N/A
- LPCN N/A
- EPS Growth
- DTSS N/A
- LPCN N/A
- EPS
- DTSS N/A
- LPCN N/A
- Revenue
- DTSS $56,255,129.00
- LPCN $3,674,834.00
- Revenue This Year
- DTSS N/A
- LPCN N/A
- Revenue Next Year
- DTSS N/A
- LPCN N/A
- P/E Ratio
- DTSS N/A
- LPCN N/A
- Revenue Growth
- DTSS 144.20
- LPCN N/A
- 52 Week Low
- DTSS $1.63
- LPCN $2.68
- 52 Week High
- DTSS $7.67
- LPCN $8.71
- Technical
- Relative Strength Index (RSI)
- DTSS 40.28
- LPCN 51.52
- Support Level
- DTSS $1.91
- LPCN $3.13
- Resistance Level
- DTSS $2.18
- LPCN $3.53
- Average True Range (ATR)
- DTSS 0.14
- LPCN 0.24
- MACD
- DTSS -0.03
- LPCN 0.01
- Stochastic Oscillator
- DTSS 15.09
- LPCN 48.33
About DTSS Datasea Inc.
Datasea Inc is a technology company. Its offers provides acoustic business services (focusing on high-tech acoustic technologies and applications such as ultrasound, infrasound, and Schumann resonance), 5G application services (5G AI multimodal digital business), and other products and services to various corporate and individual customers. The business activity of the group functions through China.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.